Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Medical College of Wisconsin
Optimum Therapeutics, LLC
Ohio State University
Information provided by (Responsible Party):
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT01671332
First received: June 25, 2012
Last updated: August 5, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: June 29, 2016